# Temsirolimus, Bendamustine and Rituximab for Relapsed Follicular Lymphoma or Mantle Cell Lymphoma

> **NCT01078142** · PHASE1,PHASE2 · COMPLETED · sponsor: **Georg Hess, MD** · enrollment: 39 (actual)

## Conditions studied

- Follicular Lymphoma
- Mantle Cell Lymphoma

## Interventions

- **DRUG:** Temsirolimus, Rituximab, Bendamustin

## Key facts

- **NCT ID:** NCT01078142
- **Lead sponsor:** Georg Hess, MD
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-02-02
- **Primary completion:** 2017-09-08
- **Final completion:** 2017-09-08
- **Target enrollment:** 39 (ACTUAL)
- **Last updated:** 2017-09-11

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01078142

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01078142, "Temsirolimus, Bendamustine and Rituximab for Relapsed Follicular Lymphoma or Mantle Cell Lymphoma". Retrieved via AI Analytics 2026-05-29 from https://api.ai-analytics.org/clinical/NCT01078142. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*